{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:59:12Z","timestamp":1790776752836,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.xphs.2026.104455","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T05:54:36Z","timestamp":1785995676000},"page":"104455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanistic modeling of time-dependent antibody clearance in multiple myeloma: A physiologically based pharmacokinetic model of isatuximab"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2274-5607","authenticated-orcid":false,"given":"Jeffrey R.","family":"Proctor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1550-5071","authenticated-orcid":false,"given":"Harvey","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2026.104455_bib0001","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/cpt.656","article-title":"Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis","volume":"101","author":"Liu","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2026.104455_bib0002","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10928-017-9528-y","article-title":"Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response","volume":"44","author":"Li","year":"2017","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.xphs.2026.104455_bib0003","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/psp4.12406","article-title":"Time-varying clearance and impact of disease state on the pharmacokinetics of avelumab in Merkel cell carcinoma and urothelial carcinoma","volume":"8","author":"Wilkins","year":"2019","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"10.1016\/j.xphs.2026.104455_bib0004","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/psp4.12477","article-title":"Population pharmacokinetics of ipilimumab in combination with nivolumab in patients with advanced solid tumors","volume":"9","author":"Sanghavi","year":"2020","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"10.1016\/j.xphs.2026.104455_bib0005","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1111\/bcp.13271","article-title":"Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome: pharmacokinetics of rituximab and clinical outcome","volume":"83","author":"Rozman","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2026.104455_bib0006","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2125.2007.02914.x","article-title":"Population pharmacokinetics\/pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response","volume":"64","author":"Mould","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2026.104455_bib0007","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/jcph.268","article-title":"Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis","volume":"54","author":"Struemper","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2026.104455_bib0008","article-title":"Time-dependent clearance can confound exposure\u2013response analysis of therapeutic antibodies: a comprehensive review of the current literature","volume":"17","author":"Proctor","year":"2023","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.xphs.2026.104455_bib0009","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/psp4.12015","article-title":"Establishing good practices for exposure\u2013response analysis of clinical endpoints in drug development","volume":"4","author":"Overgaard","year":"2015","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"10.1016\/j.xphs.2026.104455_bib0010","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1200\/JCO.2016.71.6852","volume":"35","author":"Shah","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.xphs.2026.104455_bib0011","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"Van De Donk","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.xphs.2026.104455_bib0012","first-page":"5","article-title":"The paraprotein - an enduring biomarker","volume":"40","author":"Tate","year":"2019","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.xphs.2026.104455_bib0013","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.xphs.2026.104455_bib0014","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2141.2008.07547.x","article-title":"Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols","volume":"145","author":"Nair","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.xphs.2026.104455_bib0015","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","article-title":"FcRn: the architect behind the immune and nonimmune functions of IgG and albumin","volume":"194","author":"Pyzik","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.xphs.2026.104455_bib0016","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.xphs.2026.104455_bib0017","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/psp4.12666","article-title":"PK\/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma","volume":"10","author":"Koiwai","year":"2021","journal-title":"CPT Pharmacom Syst Pharma"},{"key":"10.1016\/j.xphs.2026.104455_bib0018","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1081-1206(10)60665-5","article-title":"Assessment and clinical interpretation of reduced IgG values","volume":"99","author":"Agarwal","year":"2007","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.xphs.2026.104455_bib0019","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/cncr.33448","article-title":"Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed\/refractory multiple myeloma","volume":"127","author":"Martin","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.xphs.2026.104455_bib0020","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1182\/blood.2020008209","article-title":"Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Dimopoulos","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.xphs.2026.104455_bib0021","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-18-1597","article-title":"The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma","volume":"25","author":"Moreno","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.xphs.2026.104455_bib0022","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/psp4.12789","article-title":"Exposure-response analyses for selection\/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide\/dexamethasone treatment in patients with multiple myeloma","volume":"11","author":"Rachedi","year":"2022","journal-title":"CPT Pharmacom Syst Pharma"},{"key":"10.1016\/j.xphs.2026.104455_bib0023","first-page":"15628","article-title":"Population pharmacokinetics and exposure\u2013response analyses of daratumumab plus pomalidomide\/dexamethasone in relapsed or refractory multiple myeloma","author":"Dosne","year":"2022","journal-title":"Br J Clin Pharma BCP"},{"key":"10.1016\/j.xphs.2026.104455_bib0024","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/psp4.12561","article-title":"Drug-disease interaction and time-dependent population pharmacokinetics of isatuximab in relapsed\/refractory multiple myeloma patients","volume":"9","author":"Fau","year":"2020","journal-title":"CPT Pharmacomet Syst, Pharmacol,"},{"key":"10.1016\/j.xphs.2026.104455_bib0025","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-021-04365-4","article-title":"Population pharmacokinetic and exposure\u2013response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma","volume":"89","author":"Ide","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.xphs.2026.104455_bib0026","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/psp4.12561","article-title":"Drug-disease interaction and time-dependent population pharmacokinetics of isatuximab in relapsed\/refractory multiple myeloma patients","volume":"9","author":"Fau","year":"2020","journal-title":"CPT Pharmacom Syst Pharma"},{"key":"10.1016\/j.xphs.2026.104455_bib0027","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/cpt.1619","article-title":"A minimal physiologically-based pharmacokinetic model demonstrates role of the neonatal Fc receptor (FcRn) competition in drug\u2013disease interactions with antibody therapy","volume":"107","author":"Abdallah","year":"2020","journal-title":"Clin Pharma Ther"},{"key":"10.1016\/j.xphs.2026.104455_bib0028","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10928-024-09922-x","article-title":"Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins","volume":"51","author":"Liu","year":"2024","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.xphs.2026.104455_bib0029","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/tid.12424","article-title":"Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma","volume":"17","author":"Park","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.xphs.2026.104455_bib0030","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/bcp.15628","article-title":"Population pharmacokinetics and exposure\u2013response analyses of daratumumab plus pomalidomide\/dexamethasone in relapsed or refractory multiple myeloma","volume":"89","author":"Dosne","year":"2023","journal-title":"Br J Clin Pharma"},{"key":"10.1016\/j.xphs.2026.104455_bib0031","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-021-04365-4","article-title":"Population pharmacokinetic and exposure\u2013response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma","volume":"89","author":"Ide","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.xphs.2026.104455_bib0032","first-page":"122","article-title":"Multiple myeloma: beta-2-microglobulin is not a useful follow-up parameter","volume":"82","author":"Boccadoro","year":"1989","journal-title":"Acta Haematol"},{"key":"10.1016\/j.xphs.2026.104455_bib0033","first-page":"129","article-title":"Paraprotein and beta2-microglobulin analyses in multiple myeloma\u2013do we need to monitor both?","volume":"49","author":"Sinclair","year":"2003","journal-title":"Clin Lab"},{"key":"10.1016\/j.xphs.2026.104455_bib0034","first-page":"5888","article-title":"Glycosylation at the Fab portion of myeloma immunoglobulin G and increased fucosylated biantennary sugar chains: structural analysis by high-performance liquid chromatography and antibody-lectin enzyme immunoassay using Lens culinaris agglutinin","volume":"51","author":"Kinoshita","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.xphs.2026.104455_bib0035","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1100\/tsw.2011.65","article-title":"Immunoglobulin free light chain dimers in human diseases","volume":"11","author":"Kaplan","year":"2011","journal-title":"Sci World J"},{"key":"10.1016\/j.xphs.2026.104455_bib0036","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clml.2013.03.001","article-title":"Challenges with serum protein electrophoresis in assessing progression and clinical response in patients with Waldenstr\u00f6m macroglobulinemia","volume":"13","author":"Uljon","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.xphs.2026.104455_bib0037","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10928-011-9232-2","article-title":"Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human","volume":"39","author":"Shah","year":"2012","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.xphs.2026.104455_bib0038","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/19420862.2018.1462429","article-title":"Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: a comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach","volume":"10","author":"Betts","year":"2018","journal-title":"mAbs"},{"key":"10.1016\/j.xphs.2026.104455_bib0039","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.blre.2019.01.001","article-title":"Management of infectious complications in multiple myeloma patients: expert panel consensus-based recommendations","volume":"34","author":"Girmenia","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.xphs.2026.104455_bib0040","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cpt.982","article-title":"Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status","volume":"103","author":"Baverel","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2026.104455_bib0041","doi-asserted-by":"crossref","DOI":"10.1002\/psp4.70185","article-title":"Albumin levels are predictive of cachexia-induced time-dependent clearance of therapeutic antibodies: a physiologically based pharmacokinetic model of durvalumab","volume":"15","author":"Proctor","year":"2026","journal-title":"CPT Pharmacom Syst Pharma"},{"key":"10.1016\/j.xphs.2026.104455_bib0042","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1158\/1078-0432.CCR-21-2662","article-title":"Model-based characterization of the bidirectional interaction between pharmacokinetics and tumor growth dynamics in patients with metastatic Merkel cell carcinoma treated with avelumab","volume":"28","author":"Grisic","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.xphs.2026.104455_bib0043","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/psp4.13079","article-title":"Realizing the promise of Project Optimus: challenges and emerging opportunities for dose optimization in oncology drug development","volume":"13","author":"Gao","year":"2024","journal-title":"CPT Pharmacom Syst Pharma"},{"key":"10.1016\/j.xphs.2026.104455_bib0044","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/cpt.2742","article-title":"Toward Project Optimus for oncology precision medicine: multi-dimensional dose optimization enabled by quantitative clinical pharmacology","volume":"112","author":"Venkatakrishnan","year":"2022","journal-title":"Clin Pharma Ther"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926003059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926003059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:25:47Z","timestamp":1790774747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926003059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0022354926003059"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104455","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanistic modeling of time-dependent antibody clearance in multiple myeloma: A physiologically based pharmacokinetic model of isatuximab","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104455","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Pharmacists Association\u00ae.","name":"copyright","label":"Copyright"}],"article-number":"104455"}}